基本信息
views: 239
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr Haralabos Kalofonos is a Professor of Medical Oncology, Director of the Division of Oncology and Clinical Oncology Laboratory at the University of Patras, Greece. His work is multi-dimensional and includes clinical practice and basic science. Dr. Kalofonos participates in the design of clinical trials (phase II and III) organized by Cooperative Groups as well as in international multi-centered clinical trials phase II, III and IV, to evaluate the therapeutic efficacy of new anticancer agents and/or their combination with chemotherapy.
Furthermore, Dr. Kalofonos conducts research on patients’ quality of life during and after chemotherapy or targeted therapy in order to improve treatment’s serious adverse events such as pain, anemia, depression, etc. His continuing interest on the role the psychosocial factors have in patients’ total function has led to the development of Quality of Life and Supportive Care Multidisciplinary Group.
Regarding basic research, Dr. Kalofonos has considerable experience in the development and applications of monoclonal antibodies for cancer treatment. Furthermore, his scientific interest is also focused on research for markers with prognostic and predictive role in cancer using molecular oncology techniques. Clinical Oncology Laboratory has developed a bank of fresh frozen human tissues including colon cancer and non small cell lung cancer.
Clinical practice as well as basic research will contribute to understanding carcinogenesis and tumor development for cancer management improvement. Dr. Kalofonos collaborates with several Departments of the University of Patras as also with Universities, Hospitals and Institutes in Greece and abroad (Medical Research Council – Hammersmith Hospital, UK, Institute Tumori Milan, Stony Brook University, USA, etc.).
Furthermore, Dr. Kalofonos conducts research on patients’ quality of life during and after chemotherapy or targeted therapy in order to improve treatment’s serious adverse events such as pain, anemia, depression, etc. His continuing interest on the role the psychosocial factors have in patients’ total function has led to the development of Quality of Life and Supportive Care Multidisciplinary Group.
Regarding basic research, Dr. Kalofonos has considerable experience in the development and applications of monoclonal antibodies for cancer treatment. Furthermore, his scientific interest is also focused on research for markers with prognostic and predictive role in cancer using molecular oncology techniques. Clinical Oncology Laboratory has developed a bank of fresh frozen human tissues including colon cancer and non small cell lung cancer.
Clinical practice as well as basic research will contribute to understanding carcinogenesis and tumor development for cancer management improvement. Dr. Kalofonos collaborates with several Departments of the University of Patras as also with Universities, Hospitals and Institutes in Greece and abroad (Medical Research Council – Hammersmith Hospital, UK, Institute Tumori Milan, Stony Brook University, USA, etc.).
Research Interests
Papers共 623 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer Researchno. 5_Supplement (2023): P2-26
Konstantinos E Siatis,Efstathia Giannopoulou,Dimitra Manou,Panagiotis Sarantis,Michalis V Karamouzis,Sofia Raftopoulou, Konstantinos Fasseas, Fatimah Mohammed Alzahrani,Haralabos P Kalofonos,Achilleas D Theocharis
John D Mitsou,Vivian Tseveleki,Foteinos-Ioannis Dimitrakopoulos, Konstantinos Konstantinidis,Haralabos Kalofonos
Cancersno. 15 (2023)
JTO CLINICAL AND RESEARCH REPORTSno. 1 (2023): 100433-100433
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn